MINSK, 17 September (BelTA) – The Belarusian Healthcare Ministry has received a package of documents for the clinical trial of the Gam-COVID-Vac vaccine, BelTA learned from the press service of the ministry.
Leading specialists of the Belarusian Healthcare Ministry are examining the documents for multicenter clinical trial of the combined vector vaccine produced by the Gamaleya Research Institute of Epidemiology and Microbiology of the Russian Healthcare Ministry to prevent coronavirus infection caused by the virus SARS-CoV-2. The group of experts includes specialists from the Center for Examinations and Tests in Health Service, and also leading specialists in epidemiology and infectious diseases.
“The expert work in the course of a clinical trial will be focused on the possibility of obtaining reliable data on the efficiency and safety of the vaccine in accordance with the presented trial protocol, as well as ethical issues of the trial, the protection of rights and safety of its participants,” the press service said.
The vaccine study is planned to be conducted in a double-blind placebo-controlled design. The trial will be part of a large-scale study of the Gam-COVID-Vac vaccine run by Russia.
